ImmunityBio
  • ANKTIVA®
  • Clinical Trials
    • Find a Trial
    • Become a Trial
      Investigator
    • License our Cells
  • Science
    • Platforms
    • Pipeline
    • Expanded Access
    • Research
  • Approach
    • Patients
    • Trial Investigators
    • Researchers
  • Condition
    • Bladder Cancer
    • Glioblastoma
    • HIV
    • Lynch / Colon Cancer
    • Non-Hodgkin Lymphoma
    • Human Papillomavirus
    • Non-Small Cell Lung Cancer
  • Company
    • About Us
    • Investors
    • News and Events
    • Contact
  • Careers
  • Founder’s Vision
    • Cancer Moonshot 2020
    • Childhood Cancer – Sen. McCain
    • Cancer Moonshot Announcement
    • Formation of ImmunityBio
Select Page

Jefferies Virtual Healthcare Conference 2020

Jun 3, 2020 | Events

Jefferies Virtual Healthcare Conference 2020 Presentation...

NantKwest and ImmunityBio investor call to discuss the Companies’ COVID-19 therapeutic and vaccine initiatives

May 27, 2020 | Events

NantKwest and ImmunityBio investor call to discuss the Companies’ COVID-19 therapeutic and vaccine initiatives Listen to Webcast Presentation...

Bank of America 2020 Healthcare Conference

May 12, 2020 | Events

Bank of America 2020 Healthcare Conference Presentation Slides Listen to Webcast...

38th Annual J.P. Morgan Healthcare Conference

Jan 14, 2020 | Events

38th Annual J.P. Morgan Healthcare Conference Presentation...

NantKwest Key Opinion Leader Event

Dec 2, 2019 | Events

NantKwest Key Opinion Leader Event Presentation...
Next Entries »

Recent Posts

  • ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
  • ImmunityBio Reports Third-Quarter 2024 Financial Results
  • First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
  • Jefferies London Healthcare Conference
  • ImmunityBio to Participate in the Jefferies London Healthcare Conference
 

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2024 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap